Literature DB >> 28633975

Efficacy of inactivation of viral contaminants in hyperimmune horse plasma against botulinum toxin by low pH alone and combined with pepsin digestion.

Amram Torgeman1, Nurit Mador2, Marina Dorozko2, Aliza Lifshitz2, Naomi Eschar3, Moshe D White1, Dana G Wolf2, Eyal Epstein4.   

Abstract

Assuring viral safety of horse plasma-derived products is fundamental for ethical and regulatory reasons. We previously demonstrated the ability of pepsin digestion at low pH to inactivate West Nile and Sindbis viruses in horse plasma. The present study further examined the efficiency of pepsin digestion to inactivate four additional viruses: HSV-1 and BVDV (lipid-enveloped), BPV and Reo-3 (nonenveloped). These viruses were spiked into hyperimmunized horse plasma against botulinum toxin and subjected to low pH (3.2) alone or combined with pepsin digestion (1200 units/ml). Peptic digestion inactivated the lipid-enveloped viruses, whereas the nonenveloped viruses were unaffected. Interestingly, HSV-1 was rapidly inactivated by acidic pH alone (≥4.9 ± 0.6 log10), whereas a non-robust but meaningful BVDV inactivation (2.9 ± 0.7 log10) was achieved by combined low pH and pepsin. The current study demonstrated the ability of low pH alone and in combination with pepsin digestion to inactivate enveloped viral contaminants in anti-toxin horse plasma.
Copyright © 2017 International Alliance for Biological Standardization. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bovine Viral Diarrhea Virus (BVDV); Equine plasma; Herpes Simplex Virus type-1 (HSV-1); Porcine Parvovirus (PPV); Reovirus type 3 (Reo-3); Viral clearance

Mesh:

Substances:

Year:  2017        PMID: 28633975     DOI: 10.1016/j.biologicals.2017.06.003

Source DB:  PubMed          Journal:  Biologicals        ISSN: 1045-1056            Impact factor:   1.856


  4 in total

1.  A Novel Running Wheel Mouse Model for Botulism and Its Use for the Evaluation of Postsymptom Antitoxin Efficacy.

Authors:  Arieh Schwartz; Alon Ben David; Mordechai Hotoveli; Eyal Dor; Eran Diamant; Arik Vivyorka; Osnat Rosen; Amram Torgeman; Ran Zichel
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

2.  Studying the differential efficacy of postsymptom antitoxin treatment in type A versus type B botulism using a rabbit spirometry model.

Authors:  Amram Torgeman; Arieh Schwartz; Eran Diamant; Tzadok Baruchi; Eyal Dor; Alon Ben David; Avi Pass; Ada Barnea; Arnon Tal; Amir Rosner; Osnat Rosen; Ran Zichel
Journal:  Dis Model Mech       Date:  2018-09-27       Impact factor: 5.758

3.  A Rabbit Model for the Evaluation of Drugs for Treating the Chronic Phase of Botulism.

Authors:  Amram Torgeman; Eran Diamant; Eyal Dor; Arieh Schwartz; Tzadok Baruchi; Alon Ben David; Ran Zichel
Journal:  Toxins (Basel)       Date:  2021-09-24       Impact factor: 4.546

4.  Centaur antibodies: Engineered chimeric equine-human recombinant antibodies.

Authors:  Ronit Rosenfeld; Ron Alcalay; Anat Zvi; Alon Ben-David; Tal Noy-Porat; Theodor Chitlaru; Eyal Epstein; Ofir Israeli; Shirley Lazar; Noa Caspi; Ada Barnea; Eyal Dor; Inbar Chomsky; Shani Pitel; Efi Makdasi; Ran Zichel; Ohad Mazor
Journal:  Front Immunol       Date:  2022-08-19       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.